Compare Brevis (BREV) vs Enzyme (MLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brevis vs Enzyme — how do they compare? Brevis trades at Rp1,209 (market cap Rp303,05M, Rp168,03M 24h volume), while Enzyme trades at Rp30,212 (market cap Rp134,13M, Rp104,56M 24h volume). The key difference: Brevis is far larger — about 2.3× Enzyme's market cap, and Brevis's supply is capped (250M / 1B BREV (25%)) while Enzyme's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Brevis for 8 Days and Enzyme for 29 Days on average.
| BREV | MLN | |
|---|---|---|
Market Cap | Rp303,05M | Rp134,13M |
Volume (24h) | Rp168,03M | Rp104,56M |
Circulating Supply | 250M / 1B BREV (25%) | 3,3M MLN |
Typical Hold Time | 8 Days | 29 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brevis (BREV) is trading at Rp1,215.88 with a market cap of Rp304.38 million, showing a bearish technical signal as moving averages indicate strong selling pressure while oscillators remain neutral. The current price sits just below the pivot point of Rp1,219, with immediate support at Rp1,203 and resistance at Rp1,237. No recent protocol updates or ecosystem news are available, and the token has a low circulation rate of 25% with a max supply of 1 million tokens.
Overall outlook is cautious due to bearish technicals and limited liquidity. Key opportunities include potential rebounds from oversold RSI levels, but major risks involve low trading volume, high volatility, and lack of recent development activity, making it susceptible to price swings.
Enzyme (MLN) shows limited market activity with a modest market cap of Rp134,13M and circulating supply of 3,3jt tokens. The asset demonstrates relatively low volatility with an average hold time of 29 days, suggesting stable holder behavior. Trading volumes appear subdued across exchanges, indicating limited speculative interest. No significant protocol upgrades or ecosystem developments have been reported recently, though the project continues to operate its decentralized asset management platform.
Overall outlook remains cautious due to limited liquidity and trading activity. Key opportunities include potential ecosystem growth in decentralized finance asset management, while major risks include low market depth, regulatory uncertainty for DeFi protocols, and competition from larger DeFi platforms. The token's utility within its native protocol remains its primary value driver.
About Brevis
Brevis is a verifiable computing platform that enables scalable, trustless computation across blockchain, data, and AI systems. It allows complex programs and data queries to run off-chain and be verified on-chain using zero-knowledge proofs, delivering significantly lower costs and latency while preserving security and trustlessness.
Read more on BREV →About Enzyme
Enzyme is an easy-to-use on-chain asset management system that enables access to digital assets and DeFi from one simple, unified app. It provides a front-to-back execution and order management system, which provides fully automated reporting, risk management, administration, governance and operations.
Read more on MLN →
